Common use of Principal Amount; Series Treatment Clause in Contracts

Principal Amount; Series Treatment. (a) The 2022 Notes shall be initially limited to an aggregate principal amount of $700,000,000 and the 2042 Notes shall be initially limited to an aggregate principal amount of $300,000,000. The Company may, from time to time, without the consent of the Holders of either series of Notes, issue additional Notes of either series, so that such additional Notes and the outstanding Notes of such series will be consolidated together and form a single series of Securities under the Indenture as supplemented by this Supplemental Indenture. Any increase in the aggregate principal amount of either series of Notes shall be evidenced by an Officers’ Certificate to be delivered to the Trustee, without any further action by the Company. (b) Any additional Notes issued under Section 2.02(a) shall have the same terms in all respects as the corresponding series of Notes, except that interest will accrue on the additional Notes from the most recent date to which interest has been paid on the Notes of such series (other than the additional Notes) or if no interest has been paid on the outstanding Notes of such series from the first date that the outstanding Notes were originally issued under the Indenture, as supplemented by this Supplemental Indenture. (c) For all purposes of the Indenture and this Supplemental Indenture, all 2022 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (d) For all purposes of the Indenture and this Supplemental Indenture, all 2042 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (e) The Notes shall be issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.

Principal Amount; Series Treatment. (a) The 2022 2024 Notes shall initially be initially limited to an aggregate principal amount of $700,000,000 €750,000,000 and the 2042 2029 Notes shall initially be initially limited to an aggregate principal amount of $300,000,000€750,000,000. The Company may, from time to time, without the consent of the Holders of either any series of Notes, issue additional Notes of either any series, so that such additional Notes and the outstanding Notes of such series will be consolidated together and form a single series of Securities under the Indenture as supplemented by this Supplemental Indenture; provided that the Company will not issue such additional Notes as part of the same series as the outstanding Notes, unless the additional Notes are fungible with the outstanding Notes for U.S. federal income tax purposes. Any increase in the aggregate principal amount of either any series of Notes shall be evidenced by an Officers’ Certificate to be delivered to the Trustee, without any further action by the Company. (b) Any additional Notes of any series issued under Section 2.02(a) shall have the same terms in all respects as the corresponding series of Notes, except that interest will accrue on the additional Notes from the most recent date to which interest has been paid on the Notes of such series (other than the additional Notes) or if no interest has been paid on the outstanding Notes of such series from the first date that the outstanding Notes were originally issued under the Indenture, as supplemented by this Supplemental Indenture. (c) For all purposes of the Indenture and this Supplemental Indenture, all 2022 2024 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (d) For all purposes of the Indenture and this Supplemental Indenture, all 2042 2029 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (e) The Notes shall be issued in minimum denominations of $2,000 €100,000 and in integral multiples of $€1,000 in excess thereof.

Principal Amount; Series Treatment. (a) The 2022 2029 Notes shall be initially limited to an aggregate principal amount of $700,000,000 500,000,000 and the 2042 2034 Notes shall be initially limited to an aggregate principal amount of $300,000,000500,000,000. The However, the Company may, from time to time, without giving notice to or seeking the consent of the Holders of the Outstanding Notes of either series of Notesseries, issue additional Notes Securities of either any series, so that such additional Notes Securities and the outstanding Outstanding Notes of such series will shall be consolidated together and form a single series of Securities under the Indenture Indenture, as supplemented by this Supplemental Indenture; provided that if the additional Securities are not fungible with such Outstanding Notes of such series for United States federal income tax purposes, the additional Securities will have a separate CUSIP number. Any increase in the aggregate principal amount No such additional Securities of either a series of Notes shall may be evidenced by issued if an Officers’ Certificate to be delivered Event of Default has occurred and is continuing with respect to the Trustee, without any further action by the Company. (b) applicable series of Notes. Any additional Notes Securities issued under this Section 2.02(a) 2.02 shall have the same terms in all respects as the corresponding series of NotesSecurities, except that interest will accrue on the additional Notes Securities from the most recent date to which interest has been paid on the Outstanding Notes of such series (other than the additional NotesSecurities) or or, if no interest has been paid on the outstanding Outstanding Notes of such series from the first date that the outstanding Outstanding Notes of such series were originally issued under the Indenture, as supplemented by this Supplemental Indenture. (c) . For all purposes of the Indenture and this Supplemental Indenture, all 2022 NotesNotes of the same series, whether Initial Notes, Notes or additional Notes Securities issued under Section 2.02(a)2.02, shall constitute one series of Securities and shall vote together as one series of Securities. (d) For all purposes of the Indenture and this Supplemental Indenture, all 2042 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (e) The Notes shall be issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.

Principal Amount; Series Treatment. (a) The 2022 2013 Notes shall be initially limited to an aggregate principal amount of $700,000,000 300,000,000 and the 2042 2020 Notes shall be initially limited to an aggregate principal amount of $300,000,000. The Company may, from time to time, without the consent of the Holders of either series of Notes, issue additional Notes of either series, so that such additional Notes and the outstanding Notes of such series will be consolidated together and form a single series of Securities under the Indenture as supplemented by this Supplemental Indenture. Any increase in the aggregate principal amount of either series of Notes shall be evidenced by an Officers’ Certificate to be delivered to the Trustee, without any further action by the Company. (b) Any additional Notes issued under Section 2.02(a) shall have the same terms in all respects as the corresponding series of Notes, except that interest will accrue on the additional Notes from the most recent date to which interest has been paid on the Notes of such series (other than the additional Notes) or if no interest has been paid on the outstanding Outstanding Notes of such series from the first date that the outstanding Outstanding Notes were originally issued under the Indenture, as supplemented by this Supplemental Indenture. (c) For all purposes of the Indenture and this Supplemental Indenture, all 2022 2013 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (d) For all purposes of the Indenture and this Supplemental Indenture, all 2042 2020 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a), shall constitute one series of Securities and shall vote together as one series of Securities. (e) The Notes shall be issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.

Principal Amount; Series Treatment. (a) The 2022 2025 Notes shall be initially limited to an aggregate principal amount of $700,000,000 750,000,000 and the 2042 2030 Notes shall be initially limited to an aggregate principal amount of $300,000,000500,000,000. The Company may, from time to time, without the consent of the Holders of either any series of Notes, issue additional Notes of either any series, so that such additional Notes and the outstanding Notes of such series will be consolidated together and form a single series of Securities under the Indenture as supplemented by this Supplemental Indenture. Any increase in the aggregate principal amount of either any series of Notes shall be evidenced by an Officers’ Certificate to be delivered to the Trustee, without any further action by the Company. (b) Any additional Notes issued under Section 2.02(a) shall have the same terms in all respects as the corresponding series of Notes, except that interest will accrue on the such additional ACTIVE 255638934v.4 Notes from the most recent date to which interest has been paid on the Notes of such series (other than the such additional Notes) or if no interest has been paid on the outstanding Notes of such series from the first date that the such outstanding Notes were originally issued under the Indenture, as supplemented by this Supplemental Indenture; provided that, if such additional Notes are not fungible with the Initial Notes of such series for U.S. Federal income tax purposes, such additional Notes shall have a separate CUSIP number. (c) For all purposes of the Indenture and this Supplemental Indenture, all 2022 2025 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a)) or Exchange Notes, shall constitute one series of Securities and shall vote together as one series of Securities. (d) For all purposes of the Indenture and this Supplemental Indenture, all 2042 2030 Notes, whether Initial Notes, or additional Notes issued under Section 2.02(a)) or Exchange Notes, shall constitute one series of Securities and shall vote together as one series of Securities. (e) The Notes shall be issued in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.